研究等業績 - その他 - 成田 伸太郎
-
腎移植長期生着のために何が必要か 画像解析装置による定量的線維増生に及ぼす因子からの検討
三浦 喜子, 齋藤 満, 沼倉 一幸, 小原 崇, 鶴田 大, 井上 高光, 成田 伸太郎, 堀川 洋平, 土谷 順彦, 羽渕 友則, 小松田 敦, 加賀谷 英彰, 三浦 昌朋, 佐藤 滋
移植 ( (一社)日本移植学会 ) 45 ( 総会臨時 ) 158 - 158 2010年10月
-
Clinical significance of polymorphism and expression of chromogranin a and endothelin-1 in prostate cancer.
Zhiyong Ma, Norihiko Tsuchiya, Takeshi Yuasa, Mingguo Huang, Takashi Obara, Shintaro Narita, Yohei Horikawa, Hiroshi Tsuruta, Mitsuru Saito, Shigeru Satoh, Osamu Ogawa, Tomonori Habuchi
The Journal of urology 184 ( 3 ) 1182 - 8 2010年09月
PURPOSE: We investigated the clinical significance of chromogranin A and endothelin-1 polymorphism and expression in prostate cancer. MATERIALS AND METHODS: We analyzed 2 CHGA polymorphisms by polymerase chain reaction-restriction fragment length polymorphism in DNA samples of 435 patients with prostate cancer and 316 age matched male controls. Chromogranin A and endothelin-1 expression was evaluated by immunohistochemistry in prostate specimens of 114 men with prostate cancer who underwent radical retropubic prostatectomy and in 27 with bladder cancer who underwent radical cystectomy and served as controls. RESULTS: For the CHGA Glu264Asp polymorphism men with the GG genotype were at 2.05 times higher risk for prostate cancer than men with the CC genotype (p = 0.014). In men with prostate cancer higher chromogranin A immunohistochemistry grade was associated with higher stage and higher Gleason score (p = 0.011 and 0.044, respectively). Multivariate analysis showed that chromogranin A immunohistochemistry grade was an independent variable for predicting biochemical failure after radical prostatectomy (p = 0.023). Higher endothelin-1 expression was observed in prostate cancers (p = 0.011), especially those with a higher Gleason score (p = 0.042). There was no significant relationship between chromogranin A polymorphisms, and chromogranin A and endothelin-1 expression. CONCLUSIONS: Polymorphism and expression of chromogranin A and endothelin-1 have clinical significance in prostate cancer. Chromogranin A expression was an independent predictor of biochemical failure after prostatectomy in patients with localized prostate cancer.
-
Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
Takeshi Yuasa, Shinya Maita, Norihiko Tsuchiya, Zhiyong Ma, Shintaro Narita, Yohei Horikawa, Shinya Yamamoto, Junji Yonese, Iwao Fukui, Shunji Takahashi, Kiyohiko Hatake, Tomonori Habuchi
Urology 75 ( 5 ) 1131 - 7 2010年05月
OBJECTIVES: To examine Japanese patients who had received androgen-deprivation therapy (ADT) for longer periods, as it is known that ADT of patients with prostate cancer reduces their bone mineral density (BMD). However, our previous cross-sectional study revealed that short-term ADT (average, 23.5 months) does not significantly increase the prevalence of osteoporosis in Japanese patients. METHODS: The subjects consisted of 201 native Japanese patients with prostate cancer. They comprised 113 ADT-treated and 88 hormone-naive patients. Lumbar spine, total hip, and femoral neck BMDs were measured by dual-energy x-ray absorptiometry and expressed in standard deviation units relative to the scores of young adult men (T-score) or age-matched men (Z-score). Serum levels of bone metabolism markers were also measured. RESULTS: The ADT-treated patients had significantly lower BMD values, T-scores, and even Z-scores than the hormone-naive patients (P <.001). For patients who were hormone-naive, ADT-treated for less than 2 years, and ADT-treated for more than 2 years, the osteoporosis prevalence was 4.5% (4/88), 12.1% (4/33), and 10.8% (4/37), respectively. The ADT-treated patients had significantly higher serum amino-terminal telopeptide levels than the hormone-naive patients (P = .014), but significantly lower serum carboxy-terminal telopeptide of type-I collagen levels than the ADT-treated patients with bone metastasis (P <.001). CONCLUSIONS: Our cross-sectional study confirmed that both ADT-treated and hormone-naive Japanese patients with prostate cancer have low rates of osteoporosis. These findings are different from those of studies in western countries. Genetic and hormonal or other environmental factors may result in population differences in the characteristics of prostate cancer and BMD.
-
AN ORAL SMALL-MOLECULE MULTITARGETED RECEPTOR TYROSINE KINASE INHIBITOR, SUNITINIB, DEMONSTRATES GROWTH INHIBITION IN BONE METASTASIS OF RENAL CELL CANCER IN VIVO
Shinya Maita, Takeshi Yuasa, Norihiko Tsuchiya, Yoko Mitobe, Shintaro Narita, Yohei Horikawa, Iwao Fukui, Kiyohiko Hatake, Shinya Kimura, Taira Maekawa, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 183 ( 4 ) E30 - E30 2010年04月
研究発表要旨（国際会議）
-
CLINICAL RISK FACTORS FOR INCREASED INTERSTITIAL FIBROSIS BY COMPUTERIZED IMAGE ANALYSIS AFTER RENAL TRANSPLANTATION
Yoshiko Miura, Shigeru Satoh, Mitsuru Saito, Kazuyuki Numakura, Hiroshi Tsuruta, Takashi Obara, Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 183 ( 4 ) E802 - E802 2010年04月
研究発表要旨（国際会議）
-
Clinical Risk Factors for Increased Interstitial Fibrosis by Computerized Image Analysis after Renal Transplantation
Yoshiko Miura, Shigeru Satoh, Mitsuru Saito, Kazuyuki Numakura, Shintaro Narita, Yohei Horika, Norihiko Tsuchiya, Tomonori Habuchi
AMERICAN JOURNAL OF TRANSPLANTATION ( WILEY-BLACKWELL PUBLISHING, INC ) 10 408 - 408 2010年04月
研究発表要旨（国際会議）
-
COMBINATION THERAPY CONSISTING OF GEMCITABINE, CARBOPLATIN, AND DOCETAXEL (GCD) AS AN ACTIVE TREATMENT FOR ADVANCED UROTHELIAL CELL CARCINOMA
Hiroshi Tsuruta, Yohei Horikawa, Shintaro Narita, Mitsuru Saito, Takashi Obara, Kazuyuki Numakura, Shigeru Sato, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 183 ( 4 ) E659 - E659 2010年04月
研究発表要旨（国際会議）
-
GENETIC POLYMORPHISM INFLUENCES INDIVIDUAL VARIATIONS IN SERUM TESTOSTERONE LEVELS IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY
Shintaro Narita, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Yohei Horikawa, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 183 ( 4 ) E801 - E801 2010年04月
研究発表要旨（国際会議）
-
Impact of Clinical Characteristics and Pretransplant Urinary Bladder Capacity on Urodynamics One Year Posttransplantation in Adult Recipients
Takashi Obara, Shigeru Satoh, Mitsuru Saito, Kazuyuki Numakura, Hiroshi Tsuruta, Shintaro Narita, Yohei Horikawa, Norihiko Tsuchiya, Tomonori Habuchi
AMERICAN JOURNAL OF TRANSPLANTATION ( WILEY-BLACKWELL PUBLISHING, INC ) 10 254 - 254 2010年04月
研究発表要旨（国際会議）
-
Incidence, Clinical Risk Factors, Tacrolimus Pharmacokinetics, and Genomic Polymorphisms in Post Transplant Hyperuricemia in Early Stage Renal Transplant Recipients
Kazuyuki Numakura, Shigeru Satoh, Mitsuru Saito, Norihiko Tsuchiya, Yoshiko Miura, Takashi Obara, Hiroshi Tsuruta, Shintaro Narita, Yohei Horikawa, Tomonori Habuchi
AMERICAN JOURNAL OF TRANSPLANTATION ( WILEY-BLACKWELL PUBLISHING, INC ) 10 528 - 528 2010年04月
研究発表要旨（国際会議）
-
INSULIN-LIKE GROWTH FACTOR-I (IGF-I) POLYMORPHISMS PREDICT THE SURVIVAL OF PROSTATE CANCER PATIENTS WITH BONE METASTASIS AT INITIAL PRESENTATION
Norihiko Tsuchiya, Shintaro Narita, Zhiyong Ma, Yohei Horikawa, Hiroshi Tsuruta, Kazuyuki Numakura, Mitsuru Saito, Shigeru Satoh, Takamitsu Inoue, Osamu Ogawa, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 183 ( 4 ) E797 - E798 2010年04月
研究発表要旨（国際会議）
-
No Impact of Age on Dose-Adjusted Pharmacokinetics of Tacrolimus, Mycophenolic Acid and Prednisolone One Month after Renal Transplantation
Shigeru Satoh, Mitsuru Saito, Kazuyuki Numakura, Hiroshi Tsuruta, Takashi Obara, Takamitsu Inoue, Shintaro Narita, Yohei Horikawa, Norihiko Tsuchiya, Tomonori Habuchi, Hideaki Kagaya, Masatomo Miura
AMERICAN JOURNAL OF TRANSPLANTATION ( WILEY-BLACKWELL PUBLISHING, INC ) 10 322 - 322 2010年04月
研究発表要旨（国際会議）
-
POLYMORPHISMS IN THE XRCC1 AND MDM2 GENES MAY BE ASSOCIATED WITH RECURRENCE IN NON-MUSCLE INVASIVE BLADDER CANCER
Yohei Horikawa, Takamitsu Inoue, Shintaro Narita, Takashi Obara, Mitsuru Saito, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 183 ( 4 ) E306 - E306 2010年04月
研究発表要旨（国際会議）
-
TWEAK-FN14 SIGNALING REGULATES ANDROGEN-INDEPENDENT PROSTATE CANCER CELL INVASIVENESS AND CORRELATES WITH POOR PATIENT OUTCOME
Huang Mingguo, Shintaro Narita, Ma Zhiyong, Kazuyuki Numakura, Takashi Obara, Hiroshi Tsuruta, Mitsuru Saito, Yohei Horikawa, Norihiko Tsuchiya, Tomonori Habuchi
JOURNAL OF UROLOGY ( ELSEVIER SCIENCE INC ) 183 ( 4 ) E213 - E213 2010年04月
研究発表要旨（国際会議）
-
画像解析による移植腎線維組織の定量的測定と線維増生に関連する因子の解析
三浦 喜子, 齋藤 満, 沼倉 一幸, 鶴田 大, 小原 崇, 成田 伸太郎, 堀川 洋平, 土谷 順彦, 羽渕 友則, 加賀谷 英彰, 三浦 昌朋, 佐藤 滋
日本泌尿器科学会雑誌 ( (一社)日本泌尿器科学会 ) 101 ( 2 ) 220 - 220 2010年02月
-
AVP-010 秋田大学におけるドナー腎摘術の変遷から : 最良の術式は存在するか?(副腎・腎・尿管,総会賞応募ビデオ,第98回日本泌尿器科学総会)
土谷 龍彦, 成田 伸太郎, 井上 高光, 齋藤 満, 鶴田 大, 小原 崇, 沼倉 一幸, 堀川 洋平, 佐藤 滋, 羽渕 友則
日本泌尿器科学会雑誌 ( 一般社団法人 日本泌尿器科学会 ) 101 ( 2 ) 169 - 169 2010年
-
The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance.
Wei Wang, Takeshi Yuasa, Norihiko Tsuchiya, Zhiyong Ma, Shinya Maita, Shintaro Narita, Teruaki Kumazawa, Takamitsu Inoue, Hiroshi Tsuruta, Yohei Horikawa, Mitsuru Saito, Weilie Hu, Osamu Ogawa, Tomonori Habuchi
International journal of cancer 125 ( 12 ) 2836 - 43 2009年12月
Mel-18 is a member of the polycomb group (PcG) proteins, which are chromatin regulatory factors and play important roles in development and oncogenesis. This study was designed to investigate the clinical and prognostic significance of Mel-18 in patients with prostate cancer. A total of 539 native Japanese subjects consisting of 393 prostate cancer patients and 146 controls were enrolled in this study. Mel-18 genotyping was analyzed using a PCR-RFLP method and an automated sequencer using the GENESCAN software. Immunohistochemistry revealed that Mel-18 expression was diminished in high grade and high stage prostate cancers. Moreover, patients with positive Mel-18 expression had significantly longer PSA recurrence-free survival than patients negative for Mel-18 expression (p=0.038). A Mel-18 1805A/G SNP was located in the 3' untranslated region and was predicted to alter the secondary structure of the mRNA. Mel-18 mRNA expression of the 1805A allele was clearly higher than expression of the 1805G allele by allele specific quantitative RT-PCR. In multivariate analysis, a homozygous G allele genotype and negative Mel-18 expression were independent risk factors predicting high PSA recurrence after radical prostatectomy, with HRs of 2.757 (p=0.022) and 2.271 (p=0.045), respectively. Moreover, the G allele was also an independent predictor of poor cancer-specific survival with an HR of 4.658 (p=0.019) for patients with stage D2 prostate cancer. This is the first study to provide important evidence demonstrating that Mel-18 is a tumor suppressor and possible therapeutic target, as well as a diagnostic marker for poor prognosis in prostate cancer patients.
-
Laparoscopic nephrectomy in patients with renal vein and/or inferior vena cava anomalies: Video presentation.
Tomonori Habuchi, Shintaro Narita, Norihiko Tsuchiya, Teruaki Kumazawa, Yohei Horikawa, Shigeru Sato
International journal of urology : official journal of the Japanese Urological Association 16 ( 11 ) 854 - 854 2009年11月
Laparoscopic nephrectomy is a standard surgery for the treatment of many types of renal tumor, renal pelvic tumor, and benign disease. Renal vein and inferior vena cava anomalies are not uncommon, having been detected at an incidence of 2-17%. With the increasing number of patients undergoing laparoscopic nephrectomy, surgeons have more opportunities to encounter major anomalies of the renal vein and inferior vena cava. This video presents images of the management of the renal pedicle in laparoscopic nephrectomy in cases where there were anomalies of the renal vein and inferior vena cava. Patient 1 had left renal tumor with the left inferior vena cava, patient 2 had left ureteral tumor with double inferior vena cava, patient 3 had left renal tumor with double inferior vena cava and a circumaortic renal vein, patient 4 had left renal tumor with a retro-aortic renal vein, and patient 5 had left renal tumor with a circumaortic renal vein. Multiple renal arteries were present in patients 3, 4, and 5. In laparoscopic nephrectomy complicated by anomalies of the renal vein and inferior vena cava, (i) surgical staff should be alert for the potential presence of aberrant veins and multiple renal arteries that may not be visualized in preoperative imaging. (ii) An anterior transperitoneal approach is well-suited in the understanding of positional relationships of vessels and anatomical landmarks in cases of vascular anomalies. (iii) With recent advances in diagnostic imaging modalities, such as multislice computed tomography (CT) and 3-D CT, it has become easier to identify the major arterial and venous anomalies. However, intraoperative observation and assessment remain important and mandatory in the management of smaller anomalous vessels accompanied by major anomalies.
-
Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer.
Norihiko Tsuchiya, Shintaro Narita, Teruaki Kumazawa, Takamitsu Inoue, Zhiyong Ma, Hiroshi Tsuruta, Mitsuru Saito, Yohei Horikawa, Takeshi Yuasa, Shigeru Satoh, Osamu Ogawa, Tomonori Habuchi
Oncology reports 22 ( 3 ) 493 - 9 2009年09月
Matrix metalloproteinase-1 (MMP-1) is associated with cancer invasion and metastasis. The 2G allele of the polymorphic site in the MMP-1 promoter was demonstrated to have a higher transcription activity than the 1G allele. Allelic imbalance (AI) at 11q22 harboring the MMP-1 is frequently observed in various cancers and may be associated with an advanced disease. We conducted a case-control study to determine the association of the MMP-1 genotype with susceptibility to prostate cancer involving 283 prostate cancer patients and 251 controls. Furthermore, AI, retention allele of the MMP-1 promoter, and MMP-1 protein expression were analyzed in 77 prostate cancer specimens. The MMP-1 promoter polymorphism was associated with neither susceptibility nor progression of prostate cancer. Tumors with 1G/2G and 2G/2G genotypes had a significantly higher MMP-1 expression level compared to those with 1G/1G genotype (P=0.006 and 0.013, respectively). AI at 11q22 was observed in 13 (40.6%) of 32 informative cases. Retention of the 1G and 2G alleles were observed in 4 and 9 cases, respectively. AI was significantly associated with the Gleason score (P=0.003) and pathological stage (P=0.022). In addition, retention of the 2G allele showed a significant association with the pathological stage (P=0.026). AI at 11q22 region, retention of the 2G allele, specifically appeared to be involved in the progression of prostate cancer. However, the presence of the 2G allele of the MMP-1 promoter polymorphism itself seems to influence neither the susceptibility nor the progression of prostate cancer.